$ELV

PERU RAMIRO G purchased $366K of ELV

PERU RAMIRO G purchased 1,000 shares of Elevance Health, Inc. (ELV) at $366.05 ($0.37M total) on 2026-07-17.

Original reporting
SEC EDGAR · PERU RAMIRO G
Published Jul 17, 2026, 7:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 7:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ELV
Bullish
medium confidence
Mentioned
$ELV
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVBullishLow
01

Why it matters

The newest concrete fact is the director’s open-market purchase of 1,000 shares at a stated price on 2026-07-17.

02

Market read

Traders may monitor for follow-on insider activity, but this single Form 4 purchase is unlikely to move the stock materially by itself.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on prior holdings changes beyond the post-transaction share count.

Relevance 5/10Novelty 5/10Timing: filed same day, 2026-07-17 (after-hours/late session disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVBullishMedium confidence
Context

Elevance Health director PERU RAMIRO G bought 1,000 shares on 2026-07-17 at $366.05, totaling $366,050, per Form 4.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction size and lack of 10b5-1 pre-arrangement details reduce signal strength for trading decisions.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or non-informational motives, so the signal may be weak.

Key entities

  • Elevance Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • PERU RAMIRO G

    Director who purchased 1,000 shares on 2026-07-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVHighAI 8/10

AI Efficiency Gains And Behavioral Health Push Could Be A Game Changer For Elevance Health (ELV)

Elevance Health (ELV) reported stronger Q2 2026 results, raising full-year EPS guidance to at least $20.10. The company highlighted AI-driven efficiency gains and appointed a new leader for its behavioral health services. Analysts note potential margin improvements but caution about elevated medical costs and policy risks. Revenue and earnings projections for 2029 are $209.8 billion and $7.3 billion, respectively.

$ELVHighAI 9/10

Elevance Health Stock Outlook: Is Wall Street Bullish or Bearish?

Elevance Health (ELV) has a market cap of $86.9B. Its stock rose 27.6% over 52 weeks, outperforming the S&P 500. Q2 2026 revenue was $49.8B, adjusted EPS $7.45. The company raised EPS and cash flow guidance. Analysts expect a 10.3% YOY EPS decline for 2026, but ELV has beaten estimates for four straight quarters. The consensus rating is 'Moderate Buy' with a mean price target of $445.71.

$ELVMed

Elevance accuses Hamaspik of poaching staff to copy its plans

Elevance Health filed a complaint on July 27, 2026, in the US District Court for the Southern District of New York against managed care organization Hamaspik, Inc. and four of its own former employees. According to the filing, Hamaspik has run a "coordinated scheme" since December 2025 to hire the people who run Elevance's New York Managed Long-Term Care (MLTC) and Fully Integrated Dual Eligible Special Needs (FIDE) plans, which combine Medicare and Medicaid coverage in a single product.